Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers

Rheumatoid Arthritis

The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit

Swiss Med Wkly.

Salaffi F, Carotti M, Di Carlo M, Tardella M, Lato V, Becciolini A, Favalli EG, Giovagnoni A

doi: smw.2018.14656.

Rheumatoid Arthritis

Gaps in Addressing Cardiovascular Risk in Rheumatoid Arthritis: Assessing Performance using Cardiovascular Quality Indicators

J Rheumatol.

Barber CE, Esdaile JM, Martin LO, Faris P, Barnabe C, Guo S, Lopatina E, Marshall DA

doi: 10.3899/jrheum.160241

Rheumatoid Arthritis

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Rheumatology (Oxford).

Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G

doi: 10.1093/rheumatolog/key309.

Rheumatoid Arthritis

The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis.

J Rheumatol.

Dessein PH, Corrales A, Lopez-Mejias R, Solomon A, Woodiwiss AJ, Llorca J, Norton GR, Genre F, Blanco R, Pina T, Gonzalez-Juanatey C, Tsang L, Gonzalez-Gay MA

doi: 10.3899/jrheum.150510.

Rheumatoid Arthritis

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Arthritis Rheumatol.

Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, Biswas P, McInnes IB

doi: 10.1002/art.40911.

Psoriatic ArthritisRheumatoid Arthritis

Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations

Ther Adv Musculoskelet Dis.

Tournadre A, Mathieu S, Soubrier M

doi: 10.1177/1759720X16664306

Rheumatoid Arthritis

Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis

Rheumatology (Oxford).

Carpenter L, Nikiphorou E, Kiely PDW, Walsh DA, Young A, Norton S

doi: 10.1093/rheumatology/kez635.

Psoriatic ArthritisRheumatoid Arthritis

Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.

Rheumatol Int.

Nissen CB, Hørslev-Petersen K, Primdahl J

Rheumatoid Arthritis

Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents

Clin Exp Rheumatol.

Rodriguez-Rodriguez L, Leon L, Ivorra-Cortes J, Gómez A, Lamas JR1, Pato E, Jover JA, Abásolo L

Related content

The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit

Gaps in Addressing Cardiovascular Risk in Rheumatoid Arthritis: Assessing Performance using Cardiovascular Quality Indicators

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis.

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations

Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis

Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.

Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents